MERSML0534-25MG - ≥94% (HPLC), powder, YAP-TEA domain interaction inhibitor

Application
Verteporfin has been used as a photosensitiser. It is also used as an inhibitor of YAP (Yes-associated protein)-TEA domain (TEAD) interaction.

Biochem/physiol Actions
Verteporfin has an ability to disrupt the interaction between YAP (Yes-associated protein)/TAZ (transcriptional coactivator with PDZ-binding motif) and TEA domain (TEAD) complex. It also reduces the viability of the ovarian cancer cells and almost eliminates cell migration. Therefore, verteporfin might be considered as a potent therapeutic for ovarian cancer.

Verteporfin is a photosensitiser for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as macular degeneration. Verteporfin accumulates in abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. Verteporfin localises predominantly in mitochondria.

Verteporfin is a photosensitiser for photodynamic therapy.